Hematopoietic colony-stimulating factor priming does not influence survival in acute myeloid leukemia: A meta-analysis of randomized trials

Leukemia

Volumn 23, Issue 4, 2009, Pages 811-813

  Sung, L ^a   Alibhai, S M H ^b   Beyene, J ^a   Gamis, A ^c   Almeida, R ^a   Smith, S ^d   Aplenc, R ^d  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c CHILDREN S MERCY HOSPITAL   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; EVENT FREE SURVIVAL; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SYSTEMATIC REVIEW;

EID: 64849094466     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.305     Document Type: Article

References (8)

1. Disis ML. Clinical use of subcutaneous G-CSF or GM-CSF in malignancy. Oncology (Williston Park) 2005; 19 (4 Suppl 2): 5-9.
2. Sung L, Nathan PC, Alibhai SM, Tomlinson GA, Beyene J. Metaanalysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med 2007; 147 400-411.
3. Becker PS. Growth factor priming in therapy of acute myelogenous leukemia. Curr Hematol Rep 2004; 3: 413-418.
4. Lowenberg B, van Putten W, Theobald M, Gmur J, Verdonck L, Sonneveld P et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003; 349: 743-752.
5. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174.
6. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
7. Thomas X, Raffoux E, Botton S, Pautas C, Arnaud P, de Revel T et al Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: A trial by the Acute Leukemia French Association (ALFA) Group. Leukemia 2007; 21: 453-461.
8. Milligan DW, Wheatley K, Littlewood T, Craig JI, Burnett AK. Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: Results of the MRC AML-HR randomized trial. Blood 2006; 107: 4614-4622.